United Therapeutics (UTHR) CEO A Sells $5.2M of Stock

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), sold 9,500 shares on October 13, 2026. The sale was valued at approximately $5.2 million, with the shares priced at $545.52 each. This planned sale comes as the company prepares for its next earnings report due on October 28, 2026.

Rothblatt's latest transaction follows a previous acquisition of 9,500 shares on June 29, 2026. In that instance, she bought the shares for about $135.42 each, demonstrating her ongoing involvement with the company's stock. The sale on October 13 was her second transaction in a short period, as she had also sold 9,500 shares valued at $5.2 million in June.

Other Institutional Activity in United Therapeutics

Several other funds have also adjusted their positions in United Therapeutics. Blackrock Inc. trimmed its stake by 105,297 shares, ending with 5,294,529 shares worth approximately $2.81 billion. Avoro Capital Advisors LLC increased its holdings by 147,804 shares, bringing its total to 2,777,777 shares valued at about $1.48 billion. Similarly, State Street Corporation grew its position by 54,030 shares, totaling 1,898,064 shares worth about $1.01 billion. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both reduced their stakes slightly, with declines of 84,359 and 39,348 shares, respectively.

United Therapeutics Corporation Stock Up 0.1%

Currently, United Therapeutics' stock trades at $541.98, which is near its 52-week high of $609.35. The stock has shown strong momentum, especially compared to its low of $409.07 over the past year. This price point suggests robust performance in the market leading up to the upcoming earnings report.

Recent Earnings

In its most recent earnings report, United Therapeutics reported revenue of approximately $3.15 billion, reflecting a slight decline in revenue growth of 1.9%. The company posted an EPS of 27.9 and a net margin of 41.6%. Investors should watch for updated quarterly results on October 28, which could provide further insights into the company's financial health.

Analysts Set New Price Targets

On October 8, 2026, RBC Capital maintained an 'Outperform' rating with a price target of $708, up from a prior target of $677. Morgan Stanley also maintained an 'Equal-Weight' rating and raised its target to $566 from $515 on October 7, 2026. Additionally, BTIG upgraded its rating to 'Buy' with a target of $728 on October 1, 2026, reflecting positive sentiment among analysts.

About United Therapeutics

United Therapeutics Corporation is focused on developing and commercializing innovative products to meet the medical needs of patients with chronic and life-threatening diseases. Headquartered in Silver Spring, MD, the company has a significant presence in the biotechnology sector, competing in the drug manufacturers industry, particularly for specialty and generic medications.

Bottom Line

Investors will be keen to see how United Therapeutics performs in its upcoming earnings announcement on October 28, 2026. Rothblatt's planned sale of shares reinforces her active management of personal holdings, while the stock's strong performance and favorable analyst ratings suggest ongoing investor interest. As always, the latest 13F filings provide a backward-looking view of institutional holdings that may not reflect current positions.